Cytokinetics (NASDAQ:CYTK) Stock Price Down 6.6% – Here’s What Happened

Cytokinetics, Incorporated (NASDAQ:CYTK)’s stock price traded down 6.6% during mid-day trading on Friday . The company traded as low as $76.40 and last traded at $75.97. Approximately 1,067,949 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 2,162,348 shares. The stock had previously closed at $81.37.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Analyst confidence increased: Needham raised its price target from $102 to $112 and reiterated a “Buy” rating, while Citizens JMP lifted its target from $105 to $110 and assigned a “Market Outperform” rating. The new targets imply roughly 44%–46% upside from the recent share price. The Fly analyst price target report
• Positive Sentiment: Second-quarter revenue and EPS beat expectations: Cytokinetics reported revenue of $28.6 million versus the approximately $17.6 million consensus estimate. Its loss of $1.50 per share was narrower than the expected $1.63 loss, providing a modest positive surprise for investors. Cytokinetics second-quarter 2026 results
• Neutral Sentiment: The balance sheet remains well funded but requires monitoring: Cytokinetics ended the quarter with approximately $1.17 billion in cash and equivalents, although operating cash outflow was $159.8 million. The company reported a $179.2 million operating loss and a $198.8 million net loss, underscoring the ongoing cost of advancing its pipeline.
• Negative Sentiment: Revenue declined sharply year over year: Quarterly revenue fell 57.1% from the prior-year period, while losses widened from $1.12 per share to $1.50 per share. Separately, third-party data showed 49 insider sales and no insider purchases over the past six months, which may add to investor caution. Cytokinetics earnings and insider activity report

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CYTK shares. Mizuho lifted their price target on Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, June 24th. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research note on Friday. Needham & Company LLC lifted their target price on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a research report on Friday. HC Wainwright boosted their target price on Cytokinetics from $136.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Citizens Jmp increased their target price on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $100.85.

Cytokinetics Trading Down 5.8%

The company has a market capitalization of $9.54 billion, a P/E ratio of -11.19 and a beta of 0.38. The stock has a 50 day moving average price of $78.91 and a 200 day moving average price of $70.86.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. During the same quarter in the prior year, the firm earned ($1.12) EPS. The company’s revenue was down 57.1% on a year-over-year basis. On average, research analysts predict that Cytokinetics, Incorporated will post -6.2 EPS for the current year.

Insider Activity

In related news, EVP Andrew Callos sold 15,000 shares of Cytokinetics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the sale, the executive vice president directly owned 58,555 shares in the company, valued at $4,337,754.40. This trade represents a 20.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B Lynne Parshall sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $74.08, for a total transaction of $370,400.00. Following the sale, the director directly owned 15,784 shares in the company, valued at $1,169,278.72. The trade was a 24.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 115,179 shares of company stock valued at $9,126,054 over the last quarter. 2.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds have recently modified their holdings of CYTK. Woodline Partners LP raised its position in shares of Cytokinetics by 676.1% during the third quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock worth $90,559,000 after acquiring an additional 1,435,422 shares during the last quarter. Norges Bank bought a new stake in Cytokinetics in the fourth quarter valued at approximately $51,281,000. Deep Track Capital LP boosted its holdings in Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after acquiring an additional 650,000 shares during the last quarter. Siren L.L.C. acquired a new stake in Cytokinetics during the 1st quarter valued at approximately $40,466,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in Cytokinetics by 151,987.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock valued at $35,949,000 after purchasing an additional 565,393 shares during the period.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.